Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-5210 10/1000mg in Healthy Fed Subjects
NCT05098886Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Started Nov 2021; status: completed.
02
Drugs
dapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05098886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098886.